Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma

NCT05102721 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Pancreatic Adenocarcinoma

Interventions

DRUG: Avelumab and Pepinemab

Sponsor

Vaccinex Inc.

Collaborators

[object Object]